UK's prostate 癌 革命: 'Biggest 裁判，公判 in a 世代' could lead to a 審査 programme that 削除するs 病気's death （死傷者）数 by 40%, 最高の，を越す 専門家s hope

• e-mail

The UK will lead a prostate 癌 革命, 始める，決める to stop four in ten deaths from the 病気.

The biggest 裁判，公判 in a 世代 will 実験（する） the 有効性 of diagnosis techniques, with a 国家の 審査 programme almost 確かな to follow.

In a major victory for the Daily Mail, the results of the £42million 裁判，公判 are 推定する／予想するd to 'transform' practice, saving thousands of lives a year.

Doctors say it will also create a 'treasure trove' of data, 見本s and images that will help in the 全世界の fight against the 病気, which kills 12,000 Brits every year.

Professor Hashim Ahmed, 議長，司会を務める of urology at 皇室の College London, 述べるd it as the 'biggest, most exciting 裁判，公判 in prostate 癌 審査 and diagnosis.'

Professor Hashim Ahmed (pictured), 議長，司会を務める of urology at 皇室の College London , 述べるd it as the 'biggest, most exciting 裁判，公判 in prostate 癌 審査 and diagnosis.'?One of six 専門家s 主要な the 裁判，公判, he told the Mail: 'This is the biggest academic 熟考する／考慮する in prostate 癌 ever 基金d in the last two or three １０年間s. It's going to 意味ありげに 転換 the needle on what we understand about prostate 癌 and how we 診断する it 早期に and 審査する for it'

One of six 専門家s 主要な the 裁判，公判, he told the Mail: 'This is the biggest academic 熟考する／考慮する in prostate 癌 ever 基金d in the last two or three １０年間s.

'It's going to 意味ありげに 転換 the needle on what we understand about prostate 癌 and how we 診断する it 早期に and 審査する for it.

'I think it's one of the most exciting things in any 癌 area that we've seen for a long time.

'It will truly have a transformative 影響 on 未来 世代s of men.'

GPs will soon start sending letters to 新採用する around 12,500 men for the first 段階 of the programme, which is 推定する／予想するd to last around three years.

They will be asked to join a 審査 programme 実験（する）ing a variety of methods 含むing the prostate-明確な／細部 antigen (PSA) 血 実験（する）, specialist 15-minute MRI ざっと目を通すs known as 'prostagrams', genetic 実験（する）ing, or a combination of different methods.

Scientists will compare the results to the general 全住民 with the same 適格（性） 基準 -men 老年の 50 to 75, or over 45 if 黒人／ボイコット or with a history of prostate 癌.

They hope to 決定する the most 効果的な method for 早期に （犯罪，病気などの）発見 and which can differentiate between 積極的な 病気 and low-危険 癌s, ありそうもない to 要求する 治療.

Up to 300,000 men will then be 招待するd to 参加する using the chosen method in the second 段階 of 研究.

They will be followed for at least a １０年間 to 跡をつける 生き残り data, と一緒に 質 of life and any 削減 in 害（を与える）s.

If there a （疑いを）晴らす 調印するs of 早期に success, 専門家s believe it could be enough to 納得させる the UK 国家の 審査 委員会 (UK NSC) to recommend 国家の 審査 within three years.

Dr Matthew Hobbs, Director of 研究 at Prostate 癌 UK which （売買）手数料，委託（する）／委員会／権限d the 裁判，公判, said it was a 'pivotal moment in the history of prostate 癌 研究'.

He said: 'What we're doing here is hugely ambitious not just in cost, but in time and numbers.

'But that is to deliberately gold plate the 証拠 so that we can make sure we change practice.

'We know that earlier diagnosis saves lives, but previous 裁判，公判s 港／避難所't been able to 証明する that enough men would be saved using PSA 実験（する）s alone, while they did show that these old 審査 methods 原因（となる）d 重要な unnecessary 害（を与える） to men.

'We must now 証明する that there are better ways to find 積極的な prostate 癌 that will save even more lives while 原因（となる）ing いっそう少なく 害（を与える）.'

The Mail has fought for nearly 25 years to raise the profile of the most ありふれた 癌 in men, recently 再発進するing its End The Needless Prostate Deaths （選挙などの）運動をする.

?More than 52,000 men are 診断するd with prostate 癌 every year on 普通の／平均（する） in the UK, making it the most ありふれた 癌 in men. Around 12,000 men die every year from the 病気 ― the 同等（の） of one every 45 minutes

The 病気 usually has no symptoms until the 癌 has grown large and more difficult to 扱う／治療する. At 現在の, men who visit the doctor's with symptoms such as たびたび（訪れる） or trouble urinating may be 申し込む／申し出d a PSA 実験（する）, although many GP 辞退する them. Pictured, human prostate 癌 独房s under a microscope

While 生き残り 率s have ３倍になるd in the past 50 years, 発射／推定s 示す that by 2040 the number of men 診断するd every year in the UK could rise to 85,000 from 52,000 now.

READ MORE:?警告 over 広げるing 癌 calamity as NHS's life-saving goal to 診断する 病気 earlier is '本気で off 的'?

宣伝

The 病気 usually has no symptoms until the 癌 has grown large and more difficult to 扱う／治療する.

At 現在の, men who visit the doctor's with symptoms such as たびたび（訪れる） or trouble urinating may be 申し込む／申し出d a PSA 実験（する）, although many GP 辞退する them.

A PSA 得点する／非難する／２０ above three is 一般に seen as a 'red 旗' for possible prostate 癌 but the 実験（する） is only around 55 per cent 正確な, meaning thousands can be sent for 生体検査s or other その上の 実験（する）s unnecessarily.

The unreliability of the PSA 実験（する） is why as yet, there is no 国家の 審査 programme, にもかかわらず 142 men a day in the UK 存在 診断するd with the 病気.

Designed in 協議 with the UK NSC and 国家の 学校／設ける for Health and Care 研究 (NIHR), it is hoped the TRANSFORM 裁判，公判 will 供給する the 証拠 needed to get it over the line to join breast, cervical and bowel 癌 審査.

Rakesh Heer, a clinician and Professor of Urology at 皇室の College London who is also 伴う／関わるd in the 裁判，公判 said: 'TRANSFORM is not only the most important diagnosis 裁判，公判 in more than two １０年間s, but it could also 証明する a game changer for prostate 癌 研究 as a whole.

'This treasure trove will help 研究員s around the world create and 実証する innovative new 実験（する）s, 治療s, and AI 道具s.'

Previous 裁判，公判s using PSA and 生体検査 to 審査する for prostate 癌 have shown that it is possible to 妨げる between eight and 20 per cent of prostate 癌 deaths depending on how 定期的に men are 審査するd.

Scientists 見積（る） that these new approaches have the 可能性のある to more than 二塁打 this 衝撃 and 減ずる prostate 癌 deaths by up to 40 per cent.

The 裁判，公判 has been designed to 確実にする those most at 危険 are 井戸／弁護士席 代表するd with 黒人／ボイコット men, who have 二塁打 the 危険 of prostate 癌, making up one in ten of those 招待するd to 参加する.

Ros Eeles, Professor of oncogenetics at The 学校／設ける of 癌 研究, London, said: 'This 裁判，公判 is a game-changer because it will 許す us to rigorously 実験（する） genetic markers on a large 規模 in men from diverse 家系s.

'This could give us the （警察などへの）密告，告訴（状） we need to use genetic 危険 得点する／非難する／２０s to identify men at 危険 of 積極的な 癌 who will need 正規の／正選手 実験（する）s, while sparing men at low-危険 unnecessary 生体検査s and 治療s.'

Andrew Stephenson, 大臣 for Health and 第２位 Care, said: 'It's fantastic to know that more people are 生き残るing 癌 in the UK than ever, but we know that's partly 負かす／撃墜する to 早期に diagnosis.

'審査 for the most ありふれた 癌 in men is コンビナート／複合体 but we're 支援 groundbreaking 裁判，公判s like this to 改善する diagnostic 過程s and save thousands more lives.'

This is our last, best hope and we have to start NOW

By PROFESSOR HASHIM AHMED?

The 審議 over prostate?癌 審査 has been 激怒（する）ing for two １０年間s.

Why is this? We know that more than 12,000 men every year in the UK die of this 癌 and that 審査 with PSA 血 実験（する）s can save lives. However, with any 審査 programme, there is a balance between the 利益s of finding and 扱う／治療するing 癌 早期に, and the 害（を与える）s of 審査.

First, we know many men without 癌 will have a high PSA 血 実験（する） and have unnecessary 生体検査s.

Second, we also know that one in three of the male 全住民 above the age of 50 will have tiny areas of 'prostate 癌' which do not grow or spread. So much so, that there is a separate 審議 激怒（する）ing over the past five years about whether we should even call them '癌'.

主要な the way: Professor Hashim Ahmed

Third, when a man has a high PSA 血 実験（する）, the 生体検査 実験（する）s we used to do to find 癌 were 無作為の, with tissue 見本s taken haphazardly from the prostate. As a result, there was a good chance we would find these low-危険 癌s and men would be 扱う／治療するd unnecessarily.

Fourth, 生体検査s have 味方する 影響s and 複雑化s. Finally, 治療s such as su rgical 除去 of the prostate or 放射（能） carry 味方する-影響s with 危険 of urinary, 性の and 支援する-passage problems.

Over the past １０年間 the UK has led the 告発（する），告訴（する）／料金 in 減ずるing those 害（を与える）s. First, by using 高度に 正確な MRI ざっと目を通すs, we can find those 癌s that need 治療 and 避ける finding many of the inconsequential low-危険 癌s. Second, most men with low-危険 and some with medium-危険 prostate 癌 are managed 安全に with active 監視 rather than 即座の active 治療. Third, surgical and 放射線療法 techniques have 改善するd.

Finally, 的d 焦点の therapy to destroy individual areas of 癌 rather than the whole prostate leads to vastly lower 味方する 影響s and can be 効果的に used in two out of five men with 早期に prostate 癌.

So if we have done so 井戸／弁護士席 in 減ずるing the 害（を与える）s of 審査, why do we not just 開始する，打ち上げる a 審査 programme?

The problem is that all of these changes have been carried out in men who get referred by their GP. We do not know whether they are enough to 減ずる the 害（を与える）s, while 保持するing the 生き残り 利益, once we start 審査 hundreds of thousands of the male 全住民. To 転換 the 審議 and 納得させる everyone, the TRANSFORM 裁判，公判 is needed to weave together the 利益s of 審査 in saving lives and the 削減s in 害（を与える）. This is our last, best hope for 審査.

It will take many years and a 抱擁する 量 of 資源s, but if we don't start now we will spend the next two １０年間s carrying on our 審議 on 審査, and let 負かす／撃墜する 世代s of men.

Professor Ahmed, of 皇室の College London, is 長，指導者 捜査官／調査官 of the TRANSFORM 熟考する／考慮する